Drugs.com - Pharma Industry News

ASCO: Encorafenib + Cetuximab + Chemo Lengthens Survival in Metastatic CRC

FRIDAY, May 30, 2025 -- For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus chemotherapy (oxaliplatin, leucovorin, and...

May 30, 2025 - 16:10
 0
ASCO: Encorafenib + Cetuximab + Chemo Lengthens Survival in Metastatic CRC
FRIDAY, May 30, 2025 -- For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus chemotherapy (oxaliplatin, leucovorin, and...
Read More

Tags:

Previous Article

16 Updates, Four New Recommendations Issued for Management of Pediatric VTE

Next Article

ASCO: AI Training Improves Accuracy of HER2 Immunohistochemistry Scoring

Related Posts

Age-, Sex-, Race-Specific Standards for Thyroid Diseases May Reclassify Many Patients

Age-, Sex-, Race-Specific Standards for Thyroid Disease...

May 14, 2025  0

Apnea During REM May Affect Brain Regions Related to Memory Consolidation

Apnea During REM May Affect Brain Regions Related to Me...

May 13, 2025  0

All-Cause Mortality Higher With Sleep Deprivation in Seniors With Epilepsy

All-Cause Mortality Higher With Sleep Deprivation in Se...

May 19, 2025  0